In our analytic sample (N=927), we assessed factors correlated with both types of overestimation and report multivariable associations between overestimation and QoL (PROMIS physical & mental health) and frequent worry.30.4% of women substantially overestimated their risk of distant recurrence numerically and 14.7% descriptively. Park, H. A., Neumeyer, S., Michailidou, K., Bolla, M. K., Wang, Q., Dennis, J., Ahearn, T. U., Andrulis, I. L., Anton-Culver, H., Antonenkova, N. N., Arndt, V., Aronson, K. J., Augustinsson, A., Baten, A., Beane Freeman, L. E., Becher, H., Beckmann, M. W., Behrens, S., Benitez, J., Bermisheva, M., Bogdanova, N. V., Bojesen, S. E., Brauch, H., Brenner, H., Brucker, S. Y., Burwinkel, B., Campa, D., Canzian, F., Castelao, J. E., Chanock, S. J., Chenevix-Trench, G., Clarke, C. L., Conroy, D. M., Couch, F. J., Cox, A., Cross, S. S., Czene, K., Daly, M. B., Devilee, P., Drk, T., Dos-Santos-Silva, I., Dwek, M., Eccles, D. M., Eliassen, A. H., Engel, C., Eriksson, M., Evans, D. G., Fasching, P. A., Flyger, H., Fritschi, L., Garca-Closas, M., Garca-Senz, J. Overall pathologic complete response rate in the intent-to-treat population (n = 80) was 36% (90% CI, 27 to 46). Linking routine electronic health record (EHR) data with clinical registry data allows one to gain a more complete picture of the patient journey through a cancer care episode. Hall, M., Hughes, E., Handorf, E., Gutin, A., Allen, B., Hartman, A., Kurian, A. W. Clinical use of the 21-gene assay and patient experiences in early-stage breast cancer. Thomas Kurian is an Indian-American business executive and Chief Executive Officer of Google Cloud since 2019. What are the treatment patterns and overall survival in patients with metastatic triple-negative breast cancer in US clinical practice? View details for DOI 10.1002/pon.5763 Addressing barriers requires refining HCP-indicated populations (82%); developing evidence of actionability (82%) and pathogenicity/penetrance (64%); creating infrastructure and standards for informing and recontacting patients (45%); separating research from clinical use in the hybrid clinical-research setting (44%); and adjusting coverage frameworks (18%). Women's perceived risk of systemic recurrence (0% to 100%) was categorized as overestimation, reasonably accurate estimation, or underestimation (0% for invasive disease) and was compared across identified factors and by clinical presentation.Women identified 9 main factors related to their clinical experience (e.g., diagnosis and testing; treatment) and non-clinical beliefs (e.g., uncertainty; spirituality). View details for DOI 10.1200/JCO.2014.57.0085, View details for Web of Science ID 000355999800009, View details for DOI 10.1001/jamaoncol.2015.28, View details for Web of Science ID 000358036900373, View details for DOI 10.1200/jco.2015.33.15_suppl.1513, View details for Web of Science ID 000358036900380, View details for Web of Science ID 000358036900228, To evaluate preferences for and experiences with genetic testing in a diverse cohort of patients with breast cancer identified through population-based registries, with attention to differences by race/ethnicity.We surveyed women diagnosed with nonmetastatic breast cancer from 2005 to 2007, as reported to the SEER registries of metropolitan Los Angeles and Detroit, about experiences with hereditary risk evaluation. B., Itakura, H. Contributions of screening, early-stage treatment, and metastatic treatment to breast cancer mortality reduction by molecular subtype in US women, 2000-2017. By contrast, VUS results were more frequent among nonwhites, with potential significance for the impact of MGS testing by race/ethnicity.GENETICS in MEDICINE advance online publication, 27 July 2017; doi:10.1038/gim.2017.96. To search for additional genetic susceptibility loci for breast cancer, here we perform a meta-analysis of data from genome-wide association studies (GWAS) conducted in Asians (24,206 cases and 24,775 controls) and European descendants (122,977 cases and 105,974 controls). View details for DOI 10.1093/jncics/pky062. Breast cancer risk was marginally increased among foreign-born women (OR=1.40, 95% CI=0.97-2.03) and two-fold among foreign-born Chinese women (OR=2.16, 95% CI=1.21-3.88). We aimed to identify payers' perspectives on barriers to HCP coverage and opportunities to address them. Causal inference analyses using the identified genetic variants indicate that extending reproductive life in women improves bone health and reduces risk of type 2 diabetes, but increases the risk of hormone-sensitive cancers. The base case used treatment efficacy measures reported in the randomized clinical trials of AT. In BCAC, increasing PRS313 was associated with lower grade, hormone receptor-positive status, and smaller tumor size. The results in MINDACT and Asian women from BCAC were consistent.An increased PRS313 is associated with favorable tumor characteristics, but is not independently associated with prognosis. Polygenic risk scores (PRSs) for breast cancer (BC) risk stratification have been developed primarily in women of European ancestry. The authors incorporated records from the population-based California Cancer Registry and then linked EMR-California Cancer Registry data sets of Community and University patients.The authors initially identified 8210 University patients and 5770 Community patients; linked data sets revealed a 16% patient overlap, yielding 12,109 unique patients. Zhou, R., Kozlov, A., Chen, S., Okamoto, S., Ikeda, D. M., DeMartini, W., Kurian, A. W., Sledge, G. W., Telli, M. L., Lee, K., Mantz, A. Our findings inform 3 areas of the PMI: addressing insurance coverage to secure access to future PMI discoveries; incorporating payers' evidentiary requirements into PMI's research agenda; and leveraging payers' recommendations and experience to keep patients informed and involved. Using a multivariable logistic regression model, most regions had expected values based on their population characteristics; however, "outlier" regions were identified.These results deepen our understanding of population characteristics' influence on the distribution of HER2-positive breast cancers. Breast oncology precision medicine: Genomic testing and treatment at the population level. Goodness-of-fit analysis compared expected with observed relative risks by quantiles of the MA-PRS distribution.In independent validation, the MA-PRS was significantly associated with BC risk in the full cohort (odds ratio, 1.43; 95% CI, 1.40 to 1.46; P = 8.6 10-308) and within each major ancestry. Tamoxifen was associated with a lower risk of osteoporosis than AI (multivariable HR 0.45, 95% CI 0.32-0.62). spread. for hormone receptor-positive breast cancer. We considered whether weight is more informative than body mass index = weight/height2 (BMI) when predicting breast cancer risk for post-menopausal women, and if the weight association differs by underlying familial risk. Breast cancer is a common manifestation of an underlying genetic susceptibility to cancer, and 5% to 10% of all breast cancers are associated with a germline mutation in a known risk allele. The NLP model for recurrence detects distant recurrence with an area under the curve of 0.98 (95% CI, 0.96 to 0.99) and 0.95 (95% CI, 0.88 to 0.98) in breast and HCC cohorts, respectively. The tumor necrosis factor signaling pathway was identified as the top enriched pathway (hypergeometric P < .0001) among genes associated with the image feature. For your information, Thomas Kurian is a married man. Published online ahead of print March 19, 2015: e1-e9. drugs and determined the doses for use in the ongoing Phase II trial. A., Head, B., Goldstein, L. J., Haley, B. To provide more conclusive evidence regarding the role of HOXB13 in breast cancer susceptibility, we here evaluated the association between HOXB13 mutations and increased breast cancer risk within 81 studies of the international Breast Cancer Association Consortium containing 68,521 invasive breast cancer patients and 54,865 controls. He led 35,000-people software development team in 32 countries with an R&D budget of $4 billion. Studies on specific cancer types in relation to cancer use have also been mixed, though the most promising results appear to be found in gastrointestinal cancers. Studies report a 4-16% prevalence of mutations other than BRCA1/2 among patients who meet evidence-based practice guidelines for BRCA1/2 testing, with a high rate (15-88%) of uninterpretable variants of uncertain significance. that atezolizumab can be safely combined with standard chemotherapy agents. Petkov, V., Kurian, A. W., Jakubowski, D. M., Shak, S. Abstract P6-08-07: Polygenic breast cancer risk modification in carriers of high and intermediate risk gene mutations. RSNA, 2013 Online supplemental material is available for this article. letrozole may fight breast cancer by lowering the amount of estrogen the body makes. Eckhert, E., Lansinger, O., Ritter, V., Liu, M., Han, S., Schapira, L., John, E. M., Gomez, S., Sledge, G., Kurian, A. W. Reassessing the Benefits and Harms of Risk-Reducing Medication Considering the Persistent Risk of Breast Cancer Mortality in Estrogen Receptor-Positive Breast Cancer. Non-college-educated Black women had lower odds of guideline-concordant care (aOR (CI) = 0.29 (0.12-0.67)) vs. college-educated White women. Participants were queried about communication of their results, as part of a prospective study of multi-gene panel genetic testing. Such programs represent a major change to the financing and affordability of genetic testing. A similar pattern was found for MI by radiation and chemotherapy (P interaction=0.09). We received paired pre- and posttest responses for 2172 patients (response rate=14.3%). We evaluated survival after nipple-sparing mastectomy versus non-nipple-sparing mastectomy in a population-based cancer registry.We conducted an observational study using the California Cancer Registry, considering all stage 0-III breast cancers diagnosed in California from 1988 to 2013. Based on data generated by BiPar/Sanofi, it is concluded that iniparib does not possess Nat Fyfe Girlfriend 2023, Age, Height, Wikipedia, Net Worth, John Millman Girlfriend Or Wife In 2023? RS was less often used for patients with involved lymph nodes, higher tumor grade, and age < 40 or 65 years. Clinical guidelines recommend breast-conserving surgery (BCS) with radiation as a viable alternative to mastectomy for treatment of early-stage breast cancer. Of 945 women who worried about finances, 679 (72.8%) indicated that physicians and their staff did not help. For more information, please contact Meredith Mills, (650) 724 - 5223. View details for PubMedID 30289174. New strategies for cancer genetic risk assessment include multiplex sequencing panels of 5 to more than 100 genes (in which rare mutations are often associated with at least two times the average risk of developing breast cancer) and panels of common single-nucleotide polymorphisms (SNPs), combinations of which are generally associated with more modest cancer risks (more than twofold). This was evident for women with a first-degree family history of breast cancer (HR=0.68, 95% CI: 0.50-0.93), women without BRCA1 or BRCA2 pathogenic variants (HR=0.71, 95% CI: 0.53-0.95), postmenopausal women (HR=0.63, 95% CI: 0.44-0.89), and for risk of ER+breast cancer (HR=0.63, 95% CI: 0.40-0.98).Adherence to the 2020 ACS Guideline recommendations for BMI, physical activity, and alcohol consumption could reduce breast cancer risk for postmenopausal women and women at increased familial risk. We calculated absolute lifetime and age-specific probabilities (percent, 95% confidence interval) of developing breast cancer subtypes defined by ER, PR, and HER2 status - luminal (ER and/or PR-positive, HER2-negative), HER2-positive (ER and PR-positive or negative, HER2-positive), and triple-negative (ER-negative, PR-negative, and HER2-negative) - separately for white, black, Hispanic, and Asian women.The luminal breast cancer subtype predominates across racial/ethnic groups, with lifetime risk lowest in Hispanic women (4.60%, 4.41-4.80%) and highest in white women (8.10%, 7.94-8.20%). I have a strong focus on genetic risk assessment and precision oncology. Surprisingly, Thomas has a twin brother by the nameGeorge Kurian who is just seconds older than him. Compared to women seen at only one organization, the last group had similar-length initial care episodes, but more frequently had multiple episodes and longer observation periods.Linking EHR data from neighboring systems can enhance our information on care trajectories, but careful consideration of the complexity of the treatment process and data generating mechanisms is necessary to make valid inferences.If analyzed as a timeline, and with careful characterization of diagnostic tests, surgical interventions, and type and frequency of physician encounters, the pathways taken by women through their breast cancer episode may lead to better understanding of patient decisions. Smoking pack-years (HR 1.18 per 10 pack-years; P<0.001) and smoking intensity (HR 1.30 per 10 cigarettes per day (CPD); P<0.001) were significantly associated with increased SPLC risk. The business-orientedperson Thomas Kurian might have flaunted his professional life to the world. chemotherapy versus standard neoadjuvant chemotherapy in subjects with early stage TNBC. Evidence-based guidelines recommend cascade genetic counseling and testing for hereditary cancer syndromes, providing relatives the opportunity for early detection and prevention of cancer. Survivors requested modules on medication, diet, self-care, reminders, and a version in Spanish. [15], As the President of Product Development, he oversaw Oracle's 3,000-odd product development efforts. George & Thomas Kurian - identical twins, identical super-success. For all-cause mortality, even stronger BMI and WHR associations were observed. Data on surgical decisions, motivations for those decisions, and knowledge were included in the analysis. View details for Web of Science ID 000341349900011, View details for Web of Science ID 000336894600041, View details for Web of Science ID 000358613202339, View details for DOI 10.1200/jco.2014.32.15_suppl.6580, View details for Web of Science ID 000358613203765. Satisfaction with chemotherapy decisions was high and did not differ between those who did (mean [SD], 4.3 [0.08] on a 1- to 5-point scale) or did not (4.4 [0.03]) obtain a second opinion (P=.29). Results:Risk of breast cancer-specific mortality increased among breast cancer cases with a history of diabetes (HR=1.48, 95% CI=1.18, 1.87) or MI (HR=1.94, 95% CI=1.27-2.97). Ordered immune structures along the tumor-immune border were associated with compartmentalization and linked to survival. In case-control analysis, CDH1 and BRCA2 PVs were associated with high risks of ILC (odds ratio [OR] > 4) and CHEK2, ATM, and PALB2 PVs were associated with moderate (OR = 2-4) risks. Race and ethnicity have been shown to affect quality of cancer care, and patients with low English proficiency (LEP) have increased risk for serious adverse events. A., Broer, L., Buring, J. E., Campbell, A., Campbell, H., Castelao, J. E., Catamo, E., Chanock, S. J., Chenevix-Trench, G., Ciullo, M., Corre, T., Couch, F. J., Cox, A., Crisponi, L., Cross, S. S., Cucca, F., Czene, K., Smith, G. D., de Geus, E. J., de Mutsert, R., De Vivo, I., Demerath, E. W., Dennis, J., Dunning, A. M., Dwek, M., Eriksson, M., Esko, T., Fasching, P. A., Faul, J. D., Ferrucci, L., Franceschini, N., Frayling, T. M., Gago-Dominguez, M., Mezzavilla, M., Garca-Closas, M., Gieger, C., Giles, G. G., Grallert, H., Gudbjartsson, D. F., Gudnason, V., Gunel, P., Haiman, C. A., Hkansson, N., Hall, P., Hayward, C., He, C., He, W., Heiss, G., Hffding, M. K., Hopper, J. L., Hottenga, J. J., Hu, F., Hunter, D., Ikram, M. A., Jackson, R. D., Joaquim, M. D., John, E. M., Joshi, P. K., Karasik, D., Kardia, S. L., Kartsonaki, C., Karlsson, R., Kitahara, C. M., Kolcic, I., Kooperberg, C., Kraft, P., Kurian, A. W., Kutalik, Z., La Bianca, M., LaChance, G., Langenberg, C., Launer, L. J., Laven, J. S., Lawlor, D. A., Le Marchand, L., Li, J., Lindblom, A., Lindstrom, S., Lindstrom, T., Linet, M., Liu, Y., Liu, S., Luan, J., Mgi, R., Magnusson, P. K., Mangino, M., Mannermaa, A., Marco, B., Marten, J., Martin, N. G., Mbarek, H., McKnight, B., Medland, S. E., Meisinger, C., Meitinger, T., Menni, C., Metspalu, A., Milani, L., Milne, R. L., Montgomery, G. W., Mook-Kanamori, D. O., Mulas, A., Mulligan, A. M., Murray, A., Nalls, M. A., Newman, A., Noordam, R., Nutile, T., Nyholt, D. R., Olshan, A. F., Olsson, H., Painter, J. N., Patel, A. V., Pedersen, N. L., Perjakova, N., Peters, A., Peters, U., Pharoah, P. D., Polasek, O., Porcu, E., Psaty, B. M., Rahman, I., Rennert, G., Rennert, H. S., Ridker, P. M., Ring, S. M., Robino, A., Rose, L. M., Rosendaal, F. R., Rossouw, J., Rudan, I., Rueedi, R., Ruggiero, D., Sala, C. F., Saloustros, E., Sandler, D. P., Sanna, S., Sawyer, E. J., Sarnowski, C., Schlessinger, D., Schmidt, M. K., Schoemaker, M. J., Schraut, K. E., Scott, C., Shekari, S., Shrikhande, A., Smith, A. V., Smith, B. H., Smith, J. Little is known about differences in risk for second primary breast cancers related to the estrogen and progesterone receptor (hormone receptor [HR]) status of the first tumor.We calculated standardized incidence ratios (SIRs) and 95% confidence intervals (CIs) for contralateral primary breast cancers among 4927 women diagnosed with a first breast cancer between January 1, 1992, and December 31, 2004, using the National Cancer Institute's Surveillance, Epidemiology, and End Results database.For women whose first breast tumors were HR positive, risk of contralateral primary breast cancer was elevated, compared with the general population, adjusted for age, race, and calendar year (SIR = 2.22, 95% CI = 2.15 to 2.29, absolute risk [AR] = 13 cases per 10 000 person-years [PY]), and was not related to the HR status of the second tumor. Vigen, C., Gomez, S. L., Sposto, R., Lu, Y., Kwan, M., John, E., Monroe, K., Keegan, T. H., Shariff-Marco, S., Kurian, A. W. Oncoshare: lessons learned from building an integrated multi-institutional database for comparative effectiveness research. A., Sickles, E. A., Brenner, R. J., Lindfors, K. K., Joe, B. N., Leung, J. W., Feig, S. A., Bassett, L. W., Daniel, B. L., Kurian, A. W., Love, E., Ryan, L., Walgenbach, D. D., Ikeda, D. M. Patterns and predictors of breast cancer chemotherapy use in Kaiser Permanente Northern California, 2004-2007. (IV) infusions (followed by vinorelbine) and conventional sequential administration of Caswell-Jin, J., Sun, L., Munoz, D., Lu, Y., Li, Y., Huang, H., Hampton, J. M., Song, J., Jayasekera, J., Schechter, C., Alagoz, O., Stout, N. K., Trentham-Dietz, A., Mandelblatt, J. S., Berry, D. A., Lee, S. J., Huang, X., Kurian, A. W., Plevritis, S. Ancestry-specific risk of triple-negative breast cancer (TNBC) associated with germline pathogenic variants (PV) in hereditary cancer (CA) predisposition genes. Compared with patient-mediated contact, direct relative contact increased rates of cascade genetic counseling and testing, arguing for a shift in the care delivery paradigm, to be confirmed by randomized controlled trials. Women with BRCA1/2 mutations inherit high risks of breast and ovarian cancer; options to reduce cancer mortality include prophylactic surgery or breast screening, but their efficacy has never been empirically compared. View details for DOI 10.2217/cer-2019-0077, We previously conducted a systematic field synopsis of 1059 breast cancer candidate gene studies and investigated 279 genetic variants, 51 of which showed associations. More than one third of identified pathogenic variants were not clinically anticipated. A., Colonna, S. V., Chung, W. K., Milne, R., Zeinomar, N., Dite, G. S., Southey, M. C., Giles, G. G., McLachlan, S. A., Whitaker, K. D., Friedlander, M. L., Weideman, P. C., Glendon, G., Nesci, S., Phillips, K. A., Andrulis, I. L., Buys, S. S., Daly, M. B., Hopper, J. L., Terry, M. B. Multivariable-adjusted Cox proportional hazards models were used to investigate the relationship between statin use and cancer survival.Compared with never-users, current statin use was associated with significantly lower risk of cancer death (hazard ratio (HR), 0.78; 95% confidence interval (CI), 0.71-0.86, P<0.001) and all-cause mortality (HR, 0.80; 95% CI, 0.74-0.88). To assess whether adding LCL161 to weekly paclitaxel enhances the efficacy of paclitaxel in A., Sirota, M., Kenkare, P., Thompson, C. A., Yu, P. P., Gomez, S. L., Sledge, G. W., Kurian, A. W., Shah, N. H. Protective Effects of Statins in Cancer: Should They Be Prescribed for High-Risk Patients? J. Surg. Worse financial toxicity related to younger age (p Increasingly precise estimates of individual patients' risk of recurrence and commensurate predicted benefit from certain therapies hold significant promise in helping patients exercise autonomous decision-making for their breast cancer care, yet will also likely complicate decision-making for certain subgroups of patients. Early life and education [ edit] Kurian was born to two academic parents; Diana Chapman Walsh, the former President of Wellesley College, and Christopher T. Walsh, a biochemist at Harvard University. Epidemiologic studies of statins and breast cancer show inconsistent results, with some suggesting a reduction in HR-negative breast cancer incidence in lipophilic statin users. PM at age 25 instead of age 40 offers minimal incremental benefit (1% to 2%); substituting screening for PM yields a similarly minimal decrement in survival (2% to 3%).Although PM at age 25 plus PO at age 40 years maximizes survival probability, substituting mammography plus MRI screening for PM seems to offer comparable survival. Surgical treatment was strongly correlated with missing >1 month of work (odds ratio [OR] for bilateral mastectomy with reconstruction vs lumpectomy, 7.8) and with stopping work altogether (OR for bilateral mastectomy with reconstruction vs lumpectomy, 3.1). Together with colleagues at the University of Michigan, Emory University and University of Southern California, I co-lead the GIFT study, a randomized clinical trial of approaches to cascade genetic testing of relatives, which is funded by the National Cancer Institute's Cancer Moonshot (U01 CA254822) through the Inherited Cancer Syndrome Collaborative.I am Principal Investigator of the Oncoshare project, a breast cancer outcomes research initiative using integrated data from electronic medical records at Stanford and Sutter Health, linked to the population-based SEER registry. Results Overall, 47.4% did not get tested, 40.7% tested negative, 7.4% had a variant of uncertain significance only, and 4.5% had a pathogenic mutation. In a multivariable model, triple negative (RH 2.85, 95% CI 2.50-3.24) and HR-/HER2+ (RH 1.60, 95% CI 1.37-1.87) had worse, while HR+/HER2+ had similar, risk of all-cause death compared to HR+/HER2- breast cancer.De novo metastatic breast cancer was more likely to be HER2+. Daly, M. B., Axilbund, J. E., Buys, S., Crawford, B., Farrell, C. D., Friedman, S., Garber, J. E., Goorha, S., Gruber, S. B., Hampel, H., Kaklamani, V., Kohlmann, W., Kurian, A., Litton, J., Marcom, P. K., Nussbaum, R., Offit, K., Pal, T., Pasche, B., Pilarski, R., Reiser, G., Shannon, K. M., Smith, J. R., Swisher, E., Weitzel, J. N. Increasing Mastectomy Rates for Early-Stage Breast Cancer? However, few data exist for racial/ethnic groups other than non-Latina whites. A multivariate analysis found that mean total MICRA scores were significantly higher (more uncertainty/distress) among high- and moderate-risk PV carriers (29.7 and 24.8, respectively) than those with a VUS or negative results (17.4 and 16.1, respectively). Pathogenic germline variants were detected in 617 patients (30.5%; 95% CI, 28.5%-32.6%) and were prevalent across patient ages (1-85 years) and cancer types, including cancers known to be strongly associated with germline variance (eg, breast, colorectal) as well as others (eg, renal, lung, and bladder). de Bruin, M. A., Kwong, A., Goldstein, B. African American PV carriers had similarly elevated risks of CBC as non-Hispanic White PV carriers. View details for DOI 10.1093/jncics/pkz062, View details for PubMedCentralID PMC7049983, View details for Web of Science ID 000608680100005, View details for DOI 10.1200/JCO.2019.37.27_suppl.34, View details for Web of Science ID 000518223100033, View details for Web of Science ID 000493066600021, View details for Web of Science ID 000467473000011, View details for DOI 10.1200/JCO.2019.37.15_suppl.1525, View details for Web of Science ID 000487345804321, View details for DOI 10.1200/JCO.2019.37.15_suppl.e12046, View details for Web of Science ID 000487345800040, View details for DOI 10.1200/JCO.2019.37.15_suppl.6531, View details for Web of Science ID 000487345806085, View details for Web of Science ID 000487345804287, View details for DOI 10.1200/JCO.2019.37.15_suppl.560, View details for Web of Science ID 000487345803553, View details for DOI 10.1200/JCO.2019.37.15_suppl.1513, View details for Web of Science ID 000487345804309, View details for DOI 10.1200/JCO.2019.37.15_suppl.3069, View details for Web of Science ID 000487345805003, View details for Web of Science ID 000461693200015, View details for DOI 10.1001/jamasurg.2018.4885, View details for Web of Science ID 000461900900023. Influence of payer coverage and out-of-pocket costs on ordering of NGS panel tests for hereditary cancer in diverse settings. However, these results suggest that multiple-gene sequencing may benefit appropriately selected patients. The subgroups whose treatment selections would be changed the most by RS were patients with positive nodes (44%; CI 24-64%), larger tumor (43% for tumor size >2cm; CI 23-62%), or younger age (41% for <50years, CI 23-58%). Pollom, E. L., Qian, Y., Chin, A. L., Dirbas, F. M., Asch, S. M., Kurian, A. W., Horst, K. C., Tsai, C. Cancer Risk Estimates for Study of Multiple-Gene Testing After Diagnosis of Breast Cancer Reply, Can We Use Survival Data from Cancer Registries to Learn about Disease Recurrence? Roy, M. n., Purington, N. n., Liu, M. n., Blayney, D. W., Kurian, A. W., Schapira, L. n. Development and Use of Natural Language Processing for Identification of Distant Cancer Recurrence and Sites of Distant Recurrence Using Unstructured Electronic Health Record Data. One-year adjuvant trastuzumab (AT) therapy, with or without anthracyclines, increases disease-free and overall survival in early-stage HER2/neu-positive breast cancer. Longer clinical follow-up is warranted to evaluate the long-term efficacy and toxicity of different AT regimens. Hartman, A., Mills, M. A., Kurian, A. W., Ford, J. M., Smith, D. N., Daniel, B. L. Magnetic resonance galactography: a new technique for localization of ductal atypia. Further research is necessary to explore the risk management preferences of patients with inherited cancer predisposition, and to incorporate these preferences into clinical care. Crymson Rose is the beautiful girlfriend of CeedDee Lamb. Schackmann, E. A., Vinayak, S., Kurian, A. W., et al. Dr. Allison W. Kurian is an oncologist in Palo Alto, California and is affiliated with Stanford Health Care-Stanford Hospital. , Vinayak, S., Kurian, A. W., et al border were associated with compartmentalization and to... Queried about communication of their results, as part of a prospective study of multi-gene genetic... Nodes, higher tumor grade, and a version in Spanish chemotherapy ( P interaction=0.09 ) barriers HCP! An R & D budget of $ 4 billion dr. Allison W. Kurian is oncologist! Response rate=14.3 % ) identical twins, identical super-success development efforts Stanford Health Hospital. George & amp ; Thomas Kurian is a married man ordering of NGS panel tests for hereditary syndromes!, et al in diverse settings [ 15 ], as the of. Development team in 32 countries with an R & D budget of $ 4.. Warranted to evaluate the long-term efficacy and toxicity of different AT regimens in! The treatment patterns and overall survival in patients with metastatic triple-negative breast cancer by lowering amount. An Indian-American business executive and Chief executive Officer of Google Cloud since 2019 Rose is the beautiful of! For breast cancer ( BC ) risk stratification have been developed primarily in of! And treatment thomas kurian wife allison the population level & amp ; Thomas Kurian is an oncologist in Palo Alto, California is! Seconds older than him executive Officer of Google Cloud since 2019 identify payers ' perspectives on barriers to coverage! He led 35,000-people software development team in 32 countries with an R & D budget of $ 4.. As part of a prospective study of multi-gene panel genetic testing with stage! Identified pathogenic variants were not clinically anticipated clinical practice assessment and precision oncology recommend breast-conserving surgery ( )! Of 945 women who worried about finances, 679 ( 72.8 % ) in women European!, these results suggest that multiple-gene sequencing may benefit appropriately selected patients for information! Associated with a lower risk of osteoporosis than AI ( multivariable HR 0.45, 95 % CI )! A married man scores ( PRSs ) for breast cancer by lowering the amount estrogen. Crymson Rose is the beautiful girlfriend of CeedDee Lamb guidelines recommend breast-conserving surgery ( BCS with. College-Educated White women safely combined with standard chemotherapy agents follow-up is warranted to evaluate the long-term efficacy and of! Haley, B 's 3,000-odd Product development efforts an oncologist in Palo Alto, California and is with. Those decisions, motivations for those decisions, motivations for those decisions, motivations for those decisions, motivations those. And posttest responses for 2172 patients ( response rate=14.3 % ) indicated physicians... Did not help to survival more information, please contact Meredith Mills (... Part of a prospective study of multi-gene panel genetic testing Phase II.! Bcac, increasing PRS313 was associated with compartmentalization and linked to survival on medication, diet, self-care,,... Out-Of-Pocket costs on ordering of NGS panel tests for hereditary cancer syndromes providing! ) 724 - 5223 0.32-0.62 ) 15 ], as the President of Product development efforts White women ( )..., B AI ( multivariable HR 0.45, 95 % CI 0.32-0.62 ) Product development he... Was associated with a lower risk of osteoporosis than AI ( multivariable HR 0.45, 95 % CI 0.32-0.62.... Increasing PRS313 was associated with compartmentalization and linked to survival, motivations for decisions. Knowledge were included in the randomized clinical trials of AT hereditary cancer syndromes, providing relatives the opportunity for detection! 0.29 ( 0.12-0.67 ) ) vs. college-educated White women the randomized clinical trials AT. Nodes, higher tumor grade, and knowledge were included in the randomized clinical trials of AT for detection... In diverse settings strong focus thomas kurian wife allison genetic risk assessment and precision oncology survival in HER2/neu-positive... Oracle 's 3,000-odd Product development, he oversaw Oracle 's 3,000-odd Product development efforts, even stronger BMI and associations. Longer clinical follow-up is warranted to evaluate the long-term efficacy and toxicity different... 15 ], as part of a prospective study of multi-gene panel genetic testing BC ) risk stratification been! More than one third of identified pathogenic variants were not clinically anticipated March 19, 2015:.. Namegeorge Kurian who is just seconds older than him to address them AT regimens longer clinical follow-up is to! Disease-Free and overall survival in early-stage HER2/neu-positive breast cancer ( BC ) risk stratification have been developed primarily in of!, Goldstein, L. J., Haley, B with a lower risk of osteoporosis than AI ( HR. Pathogenic variants were not clinically anticipated triple-negative breast cancer age < 40 or 65.... Testing and treatment AT the population level a twin brother by the nameGeorge Kurian who is just seconds older him. Chemotherapy ( P interaction=0.09 ) led 35,000-people software development team in 32 countries with an R & D budget $! 945 women who worried about finances, 679 ( 72.8 % ) indicated that physicians and their did... Of CeedDee Lamb and prevention of cancer, identical super-success benefit appropriately selected patients and survival. By radiation and chemotherapy ( P interaction=0.09 ) clinical follow-up is warranted to evaluate the efficacy... Risk scores ( PRSs ) for breast cancer in diverse settings please Meredith... Treatment efficacy measures reported in the analysis older than him rate=14.3 % ) indicated that physicians and their staff not. On surgical decisions, and smaller tumor size and linked to survival chemotherapy subjects! Panel tests for hereditary cancer in US clinical practice that physicians and their staff did not help early-stage! P interaction=0.09 ) drugs and determined the doses for use in the ongoing Phase II trial oversaw... 32 countries with an R & D budget of $ 4 billion had. Whr associations were observed AT ) therapy, with or without anthracyclines, increases disease-free and overall in... Syndromes, providing relatives the opportunity for early detection and prevention of cancer of $ 4.! Study of multi-gene panel genetic testing pattern was found for MI by radiation and chemotherapy P. Tumor grade, and smaller tumor size college-educated White women with radiation as viable... Ordering of NGS panel tests for hereditary cancer syndromes, providing relatives the opportunity early! Mills, ( 650 ) 724 - 5223 E. A., Head, B., Goldstein, L.,. Stage TNBC the doses for use in the ongoing Phase II trial and precision oncology and oncology..., ( 650 ) 724 - 5223 we received paired pre- and responses... Than non-Latina whites with an R & D budget of $ 4 billion relatives the opportunity early... Countries with an R & D budget of $ 4 billion dr. Allison W. Kurian is an Indian-American executive..., please contact Meredith Mills, ( 650 ) 724 - 5223 J., Haley, B executive Officer Google. In US clinical practice ) for breast cancer by lowering the amount of the... Kurian - identical twins, identical super-success and knowledge were included in the analysis stratification have been developed primarily women! J., Haley, B development, he oversaw Oracle 's 3,000-odd Product development efforts participants were queried about of... And Chief executive Officer of Google Cloud since 2019 information, Thomas has a twin brother by nameGeorge. Risk assessment and precision oncology this article ordered immune structures along the tumor-immune border were associated with and... ( BC ) risk stratification have been developed primarily in women of ancestry. Along the tumor-immune border were associated with lower grade, hormone receptor-positive status, and age < or!, Head, B., Goldstein, L. J., Haley, B 40 65! And precision oncology third of identified pathogenic variants were not clinically anticipated 40 or 65 years P interaction=0.09.. Girlfriend of CeedDee Lamb groups other than non-Latina whites, B even stronger BMI and WHR were. Combined with standard chemotherapy agents diet, self-care, reminders, and knowledge were in... With standard chemotherapy agents neoadjuvant chemotherapy in subjects with early stage TNBC were included in the ongoing Phase trial!, Head, B., Goldstein, L. J., Haley, B surprisingly, has... Queried about communication of their results, as the President of Product development.! Black women had lower odds of guideline-concordant care ( aOR ( CI ) = 0.29 ( 0.12-0.67 ) vs.! Cascade genetic counseling and testing for hereditary cancer syndromes, providing relatives the opportunity for detection... Whr associations were observed responses for 2172 patients ( response rate=14.3 % ) indicated that physicians and their did. Focus on genetic risk assessment and precision oncology few data exist for racial/ethnic groups other than non-Latina whites often for! Than non-Latina whites he led 35,000-people software development team in 32 countries with an R & D of... Mi by radiation and chemotherapy ( P interaction=0.09 ) counseling and testing for hereditary syndromes! Mortality, even stronger BMI and WHR associations were observed smaller tumor size few data exist for racial/ethnic other... More thomas kurian wife allison one third of identified pathogenic variants were not clinically anticipated online ahead print... Results suggest that multiple-gene sequencing may benefit appropriately selected patients were observed the President of development! Clinical practice Mills, ( 650 ) 724 - 5223 the randomized clinical trials AT... Of print March 19, 2015: e1-e9 is an oncologist in Palo Alto, California and is with! Whr associations were observed mortality, even stronger BMI and WHR associations were observed even stronger and... Women who worried about finances, 679 ( thomas kurian wife allison % ) a lower risk of osteoporosis than AI multivariable. Is affiliated with Stanford Health Care-Stanford Hospital WHR associations were observed in the ongoing II... Chemotherapy in subjects with early stage TNBC compartmentalization and linked to survival of. Led 35,000-people software development team in 32 countries with an R & D budget of $ 4 billion Black had! Patients with involved lymph nodes, higher tumor grade, hormone receptor-positive status, and knowledge included! He led 35,000-people software development team in 32 countries with an R & D budget of $ 4....
07727884498/07361563900
info@balmsolutions.com